Immunologic findings in patients receiving methyldopa: a prospective study.
D000217:Acyltransferases / Q000097:blood; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis*; D000974:Antibodies, Antinuclear / Q000032:analysis; D001327:Autoimmune Diseases / Q000139:chemically induced; D044383:Black People; D003165:Complement System Proteins / Q000032:analysis; D003298:Coombs Test; D005260:Female; D006242:Haptoglobins / Q000032:analysis; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage / Q000009:adverse effects; D006973:Hypertension / Q000188:drug therapy; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000009:adverse effects*; D009504:Neutrophils; D011446:Prospective Studies; D012217:Rheumatoid Factor / Q000032:analysis; D013997:Time Factors; D044465:White People
D000888:Antibodies, Anti-Idiotypic; D000974:Antibodies, Antinuclear; D006242:Haptoglobins; D006454:Hemoglobins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D006830:Hydralazine; D008750:Methyldopa; D003165:Complement System Proteins; D012217:Rheumatoid Factor; D000217:Acyltransferases